https://scholars.lib.ntu.edu.tw/handle/123456789/568528
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | SHIH-JER HSU | en_US |
dc.contributor.author | Hsu C.-S. | en_US |
dc.contributor.author | CHEN-HUA LIU | en_US |
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | CHI-LING CHEN | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | DING-SHINN CHEN | en_US |
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.date.accessioned | 2021-07-03T03:34:36Z | - |
dc.date.available | 2021-07-03T03:34:36Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984562879&doi=10.3851%2fIMP1741&partnerID=40&md5=9acbecf671ac654b29e1bf16e6461f54 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/568528 | - |
dc.description.abstract | Background: Amino acid (aa) substitutions in genotype 1 HCV core region (HCV-CR) serve as a negative predictor of treatment responses in Japanese chronic hepatitis C (CHC) patients. Whether this phenomenon could be extrapolated to non-Japanese patients remains unclear. We evaluated the effect of aa substitutions in HCV-CR on clinicopathological features and treatment responses in Taiwanese patients. Methods: Clinical and serial virological data were collected from 147 consecutive Taiwanese HCV genotype 1 patients who received pegylated interferon plus ribavirin therapy. Quantification of HCV RNA and sequences of HCV-CR were determined by molecular methods. Results: Of 147 patients, 90 (61.2%) attained rapid virological response (RVR) and 97 (66.0%) attained sustained virological response (SVR). Patients without aa substitutions in HCV-CR (coreWW) had a higher SVR than those with both aa70 and aa91 substitutions (coreMM; 70.5% versus 45.0%; P=0.039). Moreover, coreMM was associated with a higher γ-glutamyl transpeptidase level (P=0.026) as well as more severe liver fibrosis (P=0.027) than coreWW, and patients with aa70 substitution (coreMW) were associated with more severe liver steatosis and fibrosis than those without (P=0.020 and P=0.002, respectively). In multivariate analyses, lower pretreatment body mass index, milder liver fibrosis, 48 weeks of treatment and RVR, but not aa substitutions in HCV-CR, predicted a higher SVR rate. Conclusions: Although aa substitution in genotype 1 HCV-CR is associated with more severe liver fibrosis and might be a negative predictor of SVR in Taiwanese CHC patients with interferon-based therapy, RVR and other clinical factors outweigh its role in predicting SVR. ?2011 International Medical Press. | en_US |
dc.publisher | International Medical Press Ltd | en_US |
dc.relation.ispartof | Antiviral Therapy | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | amino acid; core protein; gamma glutamyltransferase; peginterferon alpha2a; ribavirin; virus RNA; adult; amino acid substitution; article; body mass; clinical feature; controlled study; core gene; disease severity; DNA polymorphism; drug efficacy; fatty liver; female; gamma glutamyl transferase blood level; genotype; hepatitis C; Hepatitis C virus; human; liver biopsy; liver fibrosis; major clinical study; male; nucleotide sequence; prediction; priority journal; RNA analysis; sequence analysis; Taiwan; treatment response; virus gene | - |
dc.title | HCV core gene polymorphisms correlate with liver fibrosis but not sustained virological response in patients with genotype 1 infection | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3851/IMP1741 | - |
dc.identifier.scopus | 2-s2.0-84984562879 | - |
dc.relation.pages | 227-235 | en_US |
dc.relation.journalvolume | 16 | en_US |
dc.relation.journalissue | 2 | en_US |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-9399-3889 | - |
crisitem.author.orcid | 0000-0003-3622-9707 | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.orcid | 0000-0001-7791-6154 | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。